CareLit Fachartikel

Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials

G Kim, J Gerich, A Salsali, T Hach, S Hantel, HJ Woerle, UC Broedl · Diabetologie und Stoffwechsel · 2014 · Heft 05

Dokument
1113424
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
G Kim, J Gerich, A Salsali, T Hach, S Hantel, HJ Woerle, UC Broedl
Ausgabe
Heft 05 / 2014
Seiten
–
Erschienen: 2014-05-06 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0034-1374997

Zusammenfassung

Background, methods: SGLT2 inhibitors increase urinary glucose excretion. It is important to identify whether this promotes UTIs and/or genital infections (GTIs). Four randomized, placebo-controlled Phase III trials investigated the effect of EMPA for 24 weeks as monotherapy, add-on to metformin, add-on to metformin + SU, or add-on to pioglitazone ± metformin in patients with T2DM. Using pooled data from these trials, which included 2477 patients (mean age 55.6 [SD 10.5] years) treated with EMPA 10 mg, EMPA 25 mg or placebo (PBO), events consistent with UTI or GTI were evaluated using prospectively defined searc…

Schlagworte

Patients Events Consistent Infections Pooled Trials Add-On Metformin Event Genital Urinary Phase Diabetologie und Stoffwechsel